Searched for
DYSLIPIDEMIA
New cholesterol guidelines urge Americans to act earlier on ‘bad’ cholesterol and other blood fats to lower lifelong heart attack and stroke risk. Here's what you need to knowThe latest guidance from the US emphasizes the importance of identifying and treating abnormal blood fats earlier. This proactive strategy ...- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- National Insurance rejects mediclaim over 'hidden hypertension': Court says insurers can't deny genuine claims without evidence; orders over Rs 2 lakh payoutNational Insurance Company has been ordered to pay over Rs 2 lakh to a Thrissur man after a Kerala consumer commission ruled that the insur...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThe price of crude oil is down again despite the escalating tensions in the Gulf region. That augurs well for markets. This does not mean t...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOil is crucial for every part of the Indian economy: From government to consumer, its price impacts spending by every stakeholder. So, till...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Cholesterol test at age 18, Non-fasting measurement: Cardiologists Suggest New Guidelines on how to prevent heart attacksThe Cardiologist Society of India (CSI) now recommends lipid profiles starting at age 18, with non-fasting measurements as the new norm. Th...
- Zydus Lifesciences launches drug for treating bad cholesterol"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- 'Ghar ka khana' for Chidambaram in Tihar JailSenior advocate Kapil Sibal, appearing for Chidambaram, told the court that the 74-year-old Congress leader was suffering from multiple ail...
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...
- Lupin gets USFDA nod for Pitavastatin tabletsThe company has received tentative approval from the United States Food and Drug Administration (USFDA) to market its Pitavastatin tablets.
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...
- Lupin launches generic Fenofibric Acid capsules in US marketLupin said its US arm has launched generic Fenofibric Acid capsules used for reducing cholesterol and fatty acids in the blood in the Ameri...
- Zydus to launch first new chemical entity by desi companyCadila Healthcare on Wednesday said that its new chemical entity (NCE), Lipaglyn , has been approved by the Drug Controller General of Indi...
- AstraZeneca India announces CRESTOR tablets launchAstraZeneca India announced the launch of CRESTOR® (rosuvastatin) 5, 10, 20 and 40 mg tablets. CRESTOR® is indicated for use in the treatme...
- Cadila files new drug application; share up nearly 1%Cadila Healthcare has filed an investigational new drug application for conducting clinical trials for molecular entity - ZYH7, to treat dy...
- Ranbaxy's cholesterol lowering drug acquired by PPDRanbaxy Laboratories on Tuesday said US-based contact research organisation PPD Inc has acquired exclusive worldwide license to develop, ma...
Load More
